Do you think it would make sense to partner Europe and Asia/Japan and give up profits/rights, or float 10 million shares here and essentially raise the same type of money?
Honestly, I do not know which way it is going to go.
BTW, $150 million upfront for Europe is probably way on the high end, out of range, considering PCYC just got $150 million (and a lot more in royalties etc) for a WORLDWIDE partnership....for a drug which docs are saying will do for lymphoma what Gleevec did for CML.
Maybe they would get $150 million...I'd be thrilled.
Personally, I wish Roche or someone of that caliber, would take a minority stake in Ariad, the same way Roche did with Genentech (yes, i know, RHHBY spun off DNA as an IPO in 1999.... but u get what im saying)